[go: up one dir, main page]

MX9803681A - Inhibicion de la expresion de membrana. - Google Patents

Inhibicion de la expresion de membrana.

Info

Publication number
MX9803681A
MX9803681A MX9803681A MX9803681A MX9803681A MX 9803681 A MX9803681 A MX 9803681A MX 9803681 A MX9803681 A MX 9803681A MX 9803681 A MX9803681 A MX 9803681A MX 9803681 A MX9803681 A MX 9803681A
Authority
MX
Mexico
Prior art keywords
ginkgolides
inhibition
membrane expression
membrane
expression
Prior art date
Application number
MX9803681A
Other languages
English (en)
Inventor
Katy Drieu
Original Assignee
Conseils De Rech S Et Soc D
Aplications Scient S A D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conseils De Rech S Et Soc D, Aplications Scient S A D filed Critical Conseils De Rech S Et Soc D
Publication of MX9803681A publication Critical patent/MX9803681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)

Abstract

Los ginkgolide pueden ser utilizados para inhibir la expresion de membrana de un receptor de benzodiazepina en un paciente y en tratamientos para combatir el exceso en la produccion de glucocorticoide.
MX9803681A 1995-11-09 1998-05-08 Inhibicion de la expresion de membrana. MX9803681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US733795P 1995-11-09 1995-11-09
US57590295A 1995-12-20 1995-12-20

Publications (1)

Publication Number Publication Date
MX9803681A true MX9803681A (es) 1998-11-29

Family

ID=26676857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803681A MX9803681A (es) 1995-11-09 1998-05-08 Inhibicion de la expresion de membrana.

Country Status (12)

Country Link
EP (1) EP0862428B1 (es)
JP (1) JP2000505057A (es)
AT (1) ATE334672T1 (es)
AU (1) AU724416B2 (es)
CA (1) CA2235416A1 (es)
CZ (1) CZ140598A3 (es)
DE (1) DE69636412T2 (es)
ES (1) ES2264802T3 (es)
HU (1) HUP9903723A3 (es)
MX (1) MX9803681A (es)
NZ (1) NZ322050A (es)
WO (1) WO1997017068A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1865319A1 (en) 1999-08-12 2007-12-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Method of testing whether a tumor is susceptible to treatment with a ginkgo biloba extract or Ginkgolide B by testing whether the cancer is characterized by an over-expression of peripheral-type benzodiazepine receptor protein
AU6768900A (en) * 1999-08-12 2001-03-13 Georgetown University Use of ginkgo extract

Also Published As

Publication number Publication date
HUP9903723A2 (hu) 2000-03-28
NZ322050A (en) 2000-07-28
EP0862428B1 (en) 2006-08-02
EP0862428A1 (en) 1998-09-09
ATE334672T1 (de) 2006-08-15
AU7571796A (en) 1997-05-29
HUP9903723A3 (en) 2000-05-29
CZ140598A3 (cs) 1998-10-14
WO1997017068A1 (en) 1997-05-15
JP2000505057A (ja) 2000-04-25
DE69636412T2 (de) 2007-03-15
CA2235416A1 (en) 1997-05-15
ES2264802T3 (es) 2007-01-16
DE69636412D1 (de) 2006-09-14
AU724416B2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
IL123131A0 (en) Use of indigestible oligosaccharides to prevent and treat diarrhea
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
AU4859793A (en) Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
AU5563396A (en) Modified anti-icam-1 antibodies and their use in the treatme nt of inflammation
AU5267698A (en) Ascending-dose dosage form
PL319784A1 (en) Keratinocytic growth factor analoques
PL323797A1 (en) Application of bisulphonates to prevent bone tissue loss associated with immunosuppressive therapy
TJ347B (en) Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia
CA2221255A1 (en) Use of selegiline to treat hearing loss in mammals
MY114428A (en) New pharmacological use of aii-receptor antagonists
NZ324118A (en) Furan-and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants
AU4202096A (en) The use of sertraline to treat cancer patients
MX9803681A (es) Inhibicion de la expresion de membrana.
IL131478A0 (en) Methods for treatment of scar tissue
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
ZA969586B (en) The use of cholinesterase inhibitors in the treatment of xerostomia
NZ319746A (en) A synergisitic combination of a beta-receptor blocker and an opioid
ZA9610073B (en) Method of using beta-interferons to treat restenosis
PL328949A1 (en) Method of treatng excessive aggression
IL123382A0 (en) Preparation for the prophylaxis and/or treatment of wool and hair loss
MX9706825A (es) El uso farmacologico de ciertos derivados de cistina.
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
UA10754A (uk) Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.